Drug Trial Radar · NCT03409744
Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
Last checked: Nov 20, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
Mar 13, 2018
Primary completion
Apr 13, 2023
Study completion Apr 13, 2023
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jan 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of the study are: * To evaluate the long-term safety and tolerability of evinacumab in patients with Homozygous Familial Hypercholesterolemia (HoFH) * To evaluate the long-term safety and tolerability of evinacumab in adolescent patients with HoFH The secondary objectives of the study are: * To evaluate the effect of evinacumab on lipid parameters in patients with HoFH * To evaluate the effect of evinacumab on lipid parameters in adolescent patients with HoFH * To evaluate the potential development of anti-evinacumab antibodies
Conditions
- Homozygous Familial Hypercholesterolemia
Interventions
evinacumabDrug
Intravenous (IV) administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Up to Week 216Time frame: Up to 216 weeks
Locations
38 sites in 12 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Los Angeles, California
Clinical Trial Site
Boca Raton, Florida
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
New York, New York
Clinical Trial Site
Cincinnati, Ohio
Clinical Trial Site
Portland, Oregon
Clinical Trial Site
Philadelphia, Pennsylvania
Clinical Trial Site
Dallas, Texas
Clinical Trial Site
Dallas, Texas
Clinical Trial Site
Camperdown, New South Wales, Australia
Clinical Trial Site
Perth, Western Australia, Australia
Regeneron Study Site
Innsbruck, Austria
Regeneron Study Site
Vienna, State of Vienna, Austria
Clinical Trial Site
Québec, Canada
Clinical Trial Site
Chicoutimi, Quebec, Canada
Regeneron Study Site
Prague, Kateřinská, Czechia
Clinical Trial Site
Dijon, Cedex, France
Clinical Trial Site
Paris, Cedex 13, France
Clinical Trial Site
Marseille, Cedex 5, France
Clinical Trial Site
Ioannina, Greece
Regeneron Study Site
Kallithea, Athens, Greece
Clinical Trial Site
Naples, Campania, Italy
Clinical Trial Site
Roma, Rome, Italy
Clinical Trial Site
Ōbu, Aichi-ken, Japan
Regeneron Study Site
Kurume, Fukuoka, Japan
Regeneron Study Site
Nishinomiya, Hyōgo, Japan
Regeneron Study Site
Kanazawa, Ishikawa-ken, Japan
Regeneron Study Site
Kita-ku, Osaka, Japan
Regeneron Study Site
Suita, Osaka, Japan
Regeneron Study Site
Suita, Osaka, Japan
Clinical Trial Site
Amsterdam, Netherlands
Regeneron Study Site
Johannesburg, Gauteng, South Africa
Regeneron Study Site
Cape Town, Western Cape, South Africa
Clinical Trial Site
Ivano-Frankivsk, Ukraine
Clinical Trial Site #1
Kharkiv, Ukraine
Clinical Trial Site #2
Kharkiv, Ukraine
Clinical Trial Site
Kyiv, Ukraine
Rgeneron Study Site
Kyiv, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.